Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients

Serum-soluble CD95 (sCD95) levels for 72 renal cell cancer patients were significantly higher than those of 17 healthy donors. Twenty-one of 72 patients had elevated (defined as more than mean of healthy donors + 2 s.d.) sCD95. The disease-specific survival rate was significantly lower in the elevat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, M, Tomita, Y, Imai, T, Saito, T, Katagiri, A, Tanikawa, T, Takeda, M, Takahashi, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363168/
https://www.ncbi.nlm.nih.gov/pubmed/10408413
http://dx.doi.org/10.1038/sj.bjc.6690576
_version_ 1782153636771528704
author Kimura, M
Tomita, Y
Imai, T
Saito, T
Katagiri, A
Tanikawa, T
Takeda, M
Takahashi, K
author_facet Kimura, M
Tomita, Y
Imai, T
Saito, T
Katagiri, A
Tanikawa, T
Takeda, M
Takahashi, K
author_sort Kimura, M
collection PubMed
description Serum-soluble CD95 (sCD95) levels for 72 renal cell cancer patients were significantly higher than those of 17 healthy donors. Twenty-one of 72 patients had elevated (defined as more than mean of healthy donors + 2 s.d.) sCD95. The disease-specific survival rate was significantly lower in the elevated sCD95 group. Serum sCD95 level was shown to be an independent prognostic factor by univariate and multivariate analysis, indicating a possible significant role in determining treatment strategies. © 1999 Cancer Research Campaign
format Text
id pubmed-2363168
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23631682009-09-10 Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients Kimura, M Tomita, Y Imai, T Saito, T Katagiri, A Tanikawa, T Takeda, M Takahashi, K Br J Cancer Regular Article Serum-soluble CD95 (sCD95) levels for 72 renal cell cancer patients were significantly higher than those of 17 healthy donors. Twenty-one of 72 patients had elevated (defined as more than mean of healthy donors + 2 s.d.) sCD95. The disease-specific survival rate was significantly lower in the elevated sCD95 group. Serum sCD95 level was shown to be an independent prognostic factor by univariate and multivariate analysis, indicating a possible significant role in determining treatment strategies. © 1999 Cancer Research Campaign Nature Publishing Group 1999-07 /pmc/articles/PMC2363168/ /pubmed/10408413 http://dx.doi.org/10.1038/sj.bjc.6690576 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Kimura, M
Tomita, Y
Imai, T
Saito, T
Katagiri, A
Tanikawa, T
Takeda, M
Takahashi, K
Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients
title Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients
title_full Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients
title_fullStr Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients
title_full_unstemmed Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients
title_short Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients
title_sort significance of serum-soluble cd95 (fas/apo-1) on prognosis in renal cell cancer patients
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363168/
https://www.ncbi.nlm.nih.gov/pubmed/10408413
http://dx.doi.org/10.1038/sj.bjc.6690576
work_keys_str_mv AT kimuram significanceofserumsolublecd95fasapo1onprognosisinrenalcellcancerpatients
AT tomitay significanceofserumsolublecd95fasapo1onprognosisinrenalcellcancerpatients
AT imait significanceofserumsolublecd95fasapo1onprognosisinrenalcellcancerpatients
AT saitot significanceofserumsolublecd95fasapo1onprognosisinrenalcellcancerpatients
AT katagiria significanceofserumsolublecd95fasapo1onprognosisinrenalcellcancerpatients
AT tanikawat significanceofserumsolublecd95fasapo1onprognosisinrenalcellcancerpatients
AT takedam significanceofserumsolublecd95fasapo1onprognosisinrenalcellcancerpatients
AT takahashik significanceofserumsolublecd95fasapo1onprognosisinrenalcellcancerpatients

Ejemplares similares